Maricel Apuli, Chief Accounting Officer at BridgeBio Pharma, Inc. (BBIO), sold 4,859 shares at $74.31 ($365K) on 2026-02-17, disclosed to the SEC on 2026-02-18.
Scheduled sale ($365k) by Chief Accounting Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $75.25 | 4,349 | $327K | 89.6% |
| 2 | $74.31 | 510 | $38K | 10.4% |
| Total | $75.15 avg | 4,859 | $365K | 100% |
| Filing → |
| BBIO | SELL | 2026-02-27 | $132K | — | Filing → |
| BBIO | SELL | 2025-12-10 | $149K | — | Filing → |
| BBIO | SELL | 2025-08-11 | $45K | — | Filing → |